LABORATORY, IMMUNOLOGICAL, AND VIROLOGICAL MONITORING DURING RENAL DISEASE
LABORATORY, IMMUNOLOGICAL, AND VIROLOGICAL MONITORING DURING RENAL DISEASE
CASE #2: CLINICAL FOLLOW-UP CONTINUED
LABORATORY, IMMUNOLOGICAL, AND VIROLOGICAL MONITORING DURING RENAL DISEASE
HIV CHARACTERISTICS AT TIME OF DIAGNOSIS
HIV-RELATED NEPHROPATHIES ASSOCIATED WITH CHANGES IN BLOOD AND KIDNEY TISSUE VIRUS LOAD
HIV-RELATED NEPHROPATHIES ASSOCIATED WITH CHANGES IN BLOOD AND KIDNEY TISSUE VIRUS LOAD
EFFECT OF VIREMIA ON KIDNEY FUNCTION
CHANGES IN VIRAL LOAD AND GFR IN A PATIENT
CLINICAL QUESTIONS
BACKGROUND
METHODS
COVARIATES
STATISTICAL ANALYSIS
BASELINE CHARACTERISTICS
RISK FACTORS IN TREATED CONTROLLERS
CONCLUSIONS
TENOFOVIR-ASSOCIATED NEPHROPATHY
CASE #3: INITIAL PRESENTATION
CASE #3 CONTINUED
RENAL BIOPSY SHOWING ACUTE TUBULAR INJURY
TENOFOVIR NEPHROTOXICITY
WORK-UP
RENAL HANDLING OF TENOFOVIR
IMPACT OF TENOFOVIR ON RENAL FUNCTION IN HIV-INFECTED, ANTIRETROVIRAL-NAIVE PATIENTS
PROXIMAL TUBULAR RENAL DYSFUNCTION
OVERALL CHANGE OF GFR FROM BASELINE (ADJUSTED MODEL)
CONCLUSIONS
SMART CONTINUATION STUDY
RISK FOR OPPORTUNISTIC DISEASE AND DEATH AFTER REINITIATING CONTINUOUS ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV PREVIOUSLY RECEIVING EPISODIC THERAPY
RENAL DISEASE BEFORE AND AFTER STUDY MODIFICATION
MORE IS BETTER?
WHERE TO GO FROM HERE?
THANK YOU!
QUESTIONS?
We request that all users complete the brief posttest and evaluation to provide feedback to course planners and presenters. Those requesting CME credit are required to complete all components to receive credit. Begin with the posttest.